Biblio
Export 2446 results:
Author Title Type [ Year] Filters: First Letter Of Keyword is A [Clear All Filters]
“Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 567-76, 2016.
, “Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 567-76, 2016.
, “Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 567-76, 2016.
, “Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population.”, J Alzheimers Dis, vol. 52, no. 1, pp. 43-50, 2016.
, “Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population.”, J Alzheimers Dis, vol. 52, no. 1, pp. 43-50, 2016.
, “Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population.”, J Alzheimers Dis, vol. 52, no. 1, pp. 43-50, 2016.
, “Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population.”, J Alzheimers Dis, vol. 52, no. 1, pp. 43-50, 2016.
, “Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population.”, J Alzheimers Dis, vol. 52, no. 1, pp. 43-50, 2016.
, “Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study.”, J Alzheimers Dis, vol. 51, no. 2, pp. 451-61, 2016.
, “Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study.”, J Alzheimers Dis, vol. 51, no. 2, pp. 451-61, 2016.
, “Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.”, J Alzheimers Dis, vol. 49, no. 2, pp. 387-98, 2016.
, “Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.”, J Alzheimers Dis, vol. 49, no. 2, pp. 387-98, 2016.
, “Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.”, J Alzheimers Dis, vol. 49, no. 2, pp. 387-98, 2016.
, “Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.”, J Alzheimers Dis, vol. 49, no. 2, pp. 387-98, 2016.
, “Associations between Serum Omega-3 Fatty Acid Levels and Cognitive Functions among Community-Dwelling Octogenarians in Okinawa, Japan: The KOCOA Study.”, J Alzheimers Dis, vol. 51, no. 3, pp. 857-66, 2016.
, “Associations between Serum Omega-3 Fatty Acid Levels and Cognitive Functions among Community-Dwelling Octogenarians in Okinawa, Japan: The KOCOA Study.”, J Alzheimers Dis, vol. 51, no. 3, pp. 857-66, 2016.
, “Associations between Serum Omega-3 Fatty Acid Levels and Cognitive Functions among Community-Dwelling Octogenarians in Okinawa, Japan: The KOCOA Study.”, J Alzheimers Dis, vol. 51, no. 3, pp. 857-66, 2016.
, “Astrocytes release HspB1 in response to amyloid-β exposure in vitro.”, J Alzheimers Dis, vol. 49, no. 1, pp. 251-63, 2016.
, “Astrocytes release HspB1 in response to amyloid-β exposure in vitro.”, J Alzheimers Dis, vol. 49, no. 1, pp. 251-63, 2016.
, “Astrocytes release HspB1 in response to amyloid-β exposure in vitro.”, J Alzheimers Dis, vol. 49, no. 1, pp. 251-63, 2016.
, “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
, “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
, “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
, “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
, “Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.
,